Publications

Any
    Any

      5596 Results

      Phase II Trial of Atezolizumab in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: SWOG S1605

      Authors
      P Black;C Tangen;P Singh;D McConkey;MS Lucia;W Lowrance;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;M Plets;IM Thompson;SP Lerner
      Journal / Conference
      European Urology Aug 16;S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.08.004. Online ahead of print
      Year
      2023
      Research Committee(s)
      Genitourinary
      PMID
      PMID37596191
      PMC
      PMC10869634
      Study Number(s)
      S1605

      Impact of race on treatment outcomes of patients with metastatic castration-sensitive prostate cancer receiving intensified androgen deprivation therapy: A post hoc analysis of the SWOG 1216 phase III trial

      Authors
      N Sayegh;U Swami;Y Jo;G Gebrael;B Haaland;S Gupta;M Plets;M Hussain;D Quinn;P Lara;I Thompson;N Agarwal
      Journal / Conference
      JAMA Netw Open Aug 1;6(8):e2326546
      Year
      2023
      Research Committee(s)
      Genitourinary
      PMID
      PMID37526936
      PMC
      PMC10394570
      Study Number(s)
      S1216

      Assessment of Financial Screening and Navigation Capabilities at NCI Community Oncology Clinics

      Authors
      A Bell-Brown;K Watabayashi;D Delaney;R Carlos;S Langer;J Unger;R Vaidya;A Darke;D Hershman;S Ramsey;V Shankaran
      Journal / Conference
      JNCI Cancer Spectrum Aug 31;7(5):pkad055. doi: 10.1093/jncics/pkad055
      Year
      2023
      Research Committee(s)
      Cancer Care Delivery
      PMID
      PMID37561111
      PMC
      PMC10471524
      Study Number(s)
      S1912CD

      Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226

      Authors
      D Rutherford;S Medley;N Henderson;C Gersch;T Vandenberg;K Albain;S Dakhil;N Tirumali;J Gralow;G Hortobagyi;L Pusztai;R Mehta;D Hayes;K Kidwell;NL Henry;W Barlow;J Rae;D Hertz
      Journal / Conference
      Pharmacogenomics Aug;24(12):665-673
      Year
      2023
      Research Committee(s)
      Breast
      PMID
      PMID37615099
      PMC
      PMC10565537
      Study Number(s)
      S0226

      Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607

      Authors
      S Hu-Lieskovan;J Moon;J Hyngstrom;K Campbell;G In;T Logan;K Kendra;D Wang;D Johnson;G Doolittle;A Tan;Ann Silk;K Grossmann;C Ryan;SP Patel;S Bellasea;M Wu;J Kirkwood;H Chen;A Ribas
      Journal / Conference
      AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster; Cancer Research Volume 83, Issue 7_Supplement 1 April 2023
      Year
      2023
      Research Committee(s)
      Melanoma
      Study Number(s)
      S1607

      Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)

      Authors
      R Vaidya;J Unger;L Qian;K Minichiello;R Herbst;D Gandara;J Neal;T Leal;J Patel;K Dragnev;S Waqar;M Edelman;E Sigal;S Adam;S Malik;C Blanke;M LeBlanc;K Kelly;J Gray;M Redman
      Journal / Conference
      JCO Precision Oncology Sep;7:e2300218
      Year
      2023
      Research Committee(s)
      Lung
      PMID
      PMID37677122
      PMC
      PMC10581630
      Study Number(s)
      LUNGMAP

      An analysis of the rate of second primary lung cancer from CALGB/Alliance 140503 trial of lobar versus sub-lobar resection for T1aN0 NSCLC

      Authors
      T Stinchcombe;X Wang;B Damman;J Mentlick;R Landreneau;D Wigle;D Jones;M Conti;A Ashrafi;M Liberman;M DePerrot;J Mitchell;R Keenan;T Bauer;D Miller;N Altorki
      Journal / Conference
      WCLC (September 9 to 12, 2023, Singapore), oral presentation #OA12.03
      Year
      2023
      Research Committee(s)
      Lung

      Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

      Authors
      C Ryan;A Saif;F Rocha;P Philip;J Hernandez;S Ahmad;H Soares
      Journal / Conference
      Ann Surg Oncol. Mar;30(3):1302-1304
      Year
      2023
      Research Committee(s)
      Gastrointestinal
      PMID
      PMID36474095
      Study Number(s)
      S2104

      Adjusted Indirect Treatment Comparison of Progression-Free Survival Associated With D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

      Authors
      B Durie;S Kumar;E Ammann;A Fu;S Kaila;A Lam;S Usmani;T Facon
      Journal / Conference
      Proceedings Society of Hematologic Oncology 2023 Annual Meeting; Lymphoma, Myeloma & Leukemia Vol 23 Suppl 1S1-S593, poster
      Year
      2023
      Research Committee(s)
      Myeloma
      Study Number(s)
      S0777

      A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts

      Authors
      Y Chae;M Othus;S Patel;F Backes;D O'Malley;M Cristea;A Naing;K Kurnit;R Eskander;S Goodrich;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock
      Journal / Conference
      AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
      Year
      2023
      Research Committee(s)
      Early Therapeutics and Rare Cancers
      Study Number(s)
      S1609